News | May 01, 2024
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
2024 full-year revenue guidance raised by US$ 2 billion
2024 full-year revenue guidance raised by US$ 2 billion
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Innovent will supply sintilimab for the collaborated clinical trial
Express Scripts to add Zepbound to National Preferred Formulary
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)